Albion Financial Group’s Quest Diagnostics DGX Stock Holding History

Albion Financial Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$2.16K	–	683
2026 Q1	$2.16K	Buy	+11	New	+$2.14K	﹤0.01%	561
2021 Q4	–	Sell	-3	Closed	–	–	629
2021 Q3	$0	Hold	3	–	–	﹤0.01%	521
2021 Q2	$0	Buy	+3	New	+$393	﹤0.01%	519
2020 Q4	$0	Buy	+3	New	+$366	﹤0.01%	490

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Albion Financial Group's DGX Position: Q2 2026 in Review

Albion Financial Group sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 11 shares — an estimated $2.16K sold.

Albion Financial Group first reported a position in DGX in Q4 2020 and held it in 4 quarters. The position peaked at $2.16K in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Albion Financial Group reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
Albion Financial Group sold 11 Quest Diagnostics shares in Q2 2026, an estimated $2.16K.
Albion Financial Group first reported a position in Quest Diagnostics in Q4 2020 and held it in 4 quarters.
Albion Financial Group's Quest Diagnostics position peaked at $2.16K in Q1 2026.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Albion Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.